The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy.
Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may occur due to accidental exposure to peanut.
Peanut allergy is one of the most common allergies among infants and young children, with a total Peanut allergy prevalence 8,640,527 in 2017, in the 7MM, estimates DelveInsight.
The therapy, Palforzia, is designed to increase the tolerance of peanut, desensitizing the patients over time. With the appr...
